Logo image of KROS

KEROS THERAPEUTICS INC (KROS) Stock Fundamental Analysis

NASDAQ:KROS - Nasdaq - US4923271013 - Common Stock

10.86  +0.34 (+3.23%)

After market: 11.06 +0.2 (+1.84%)

Fundamental Rating

3

KROS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 574 industry peers in the Biotechnology industry. KROS has a great financial health rating, but its profitability evaluates not so good. KROS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KROS has reported negative net income.
In the past year KROS has reported a negative cash flow from operations.
In the past 5 years KROS always reported negative net income.
In the past 5 years KROS always reported negative operating cash flow.
KROS Yearly Net Income VS EBIT VS OCF VS FCFKROS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

KROS has a better Return On Assets (-31.34%) than 66.14% of its industry peers.
KROS has a Return On Equity of -34.08%. This is in the better half of the industry: KROS outperforms 76.54% of its industry peers.
Industry RankSector Rank
ROA -31.34%
ROE -34.08%
ROIC N/A
ROA(3y)-32.82%
ROA(5y)-45.5%
ROE(3y)-35.98%
ROE(5y)-518.65%
ROIC(3y)N/A
ROIC(5y)N/A
KROS Yearly ROA, ROE, ROICKROS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

1.3 Margins

KROS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KROS Yearly Profit, Operating, Gross MarginsKROS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

KROS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KROS has more shares outstanding
The number of shares outstanding for KROS has been increased compared to 5 years ago.
KROS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KROS Yearly Shares OutstandingKROS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M
KROS Yearly Total Debt VS Total AssetsKROS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

KROS has an Altman-Z score of 4.34. This indicates that KROS is financially healthy and has little risk of bankruptcy at the moment.
KROS has a better Altman-Z score (4.34) than 79.37% of its industry peers.
KROS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.34
ROIC/WACCN/A
WACC10.71%
KROS Yearly LT Debt VS Equity VS FCFKROS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

KROS has a Current Ratio of 19.03. This indicates that KROS is financially healthy and has no problem in meeting its short term obligations.
KROS has a better Current ratio (19.03) than 94.36% of its industry peers.
KROS has a Quick Ratio of 19.03. This indicates that KROS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 19.03, KROS belongs to the top of the industry, outperforming 94.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 19.03
Quick Ratio 19.03
KROS Yearly Current Assets VS Current LiabilitesKROS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

KROS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.25%.
Looking at the last year, KROS shows a very strong growth in Revenue. The Revenue has grown by 6410.00%.
Measured over the past years, KROS shows a very negative growth in Revenue. The Revenue has been decreasing by -56.77% on average per year.
EPS 1Y (TTM)-5.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.02%
Revenue 1Y (TTM)6410%
Revenue growth 3YN/A
Revenue growth 5Y-56.77%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 2.81% on average over the next years.
Based on estimates for the next years, KROS will show a very strong growth in Revenue. The Revenue will grow by 602.45% on average per year.
EPS Next Y-2.09%
EPS Next 2Y-0.54%
EPS Next 3Y2.66%
EPS Next 5Y2.81%
Revenue Next Year15532.7%
Revenue Next 2Y296.32%
Revenue Next 3Y1012.85%
Revenue Next 5Y602.45%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
KROS Yearly Revenue VS EstimatesKROS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
KROS Yearly EPS VS EstimatesKROS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KROS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KROS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KROS Price Earnings VS Forward Price EarningsKROS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KROS Per share dataKROS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.54%
EPS Next 3Y2.66%

More info and screens

0

5. Dividend

5.1 Amount

KROS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KEROS THERAPEUTICS INC

NASDAQ:KROS (1/17/2025, 8:11:31 PM)

After market: 11.06 +0.2 (+1.84%)

10.86

+0.34 (+3.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners96.41%
Inst Owner Change0%
Ins Owners0.68%
Ins Owner Change0%
Market Cap439.94M
Analysts83
Price Target46.92 (332.04%)
Short Float %11.16%
Short Ratio3.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.76%
Min EPS beat(2)-8.05%
Max EPS beat(2)0.53%
EPS beat(4)3
Avg EPS beat(4)2.21%
Min EPS beat(4)-8.05%
Max EPS beat(4)11.93%
EPS beat(8)6
Avg EPS beat(8)1.46%
EPS beat(12)8
Avg EPS beat(12)7.24%
EPS beat(16)9
Avg EPS beat(16)4.33%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-49.82%
PT rev (3m)-49.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-26.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-99.35%
Revenue NY rev (1m)24.25%
Revenue NY rev (3m)-76.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 675.79
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 0.83
EV/EBITDA N/A
EPS(TTM)-5.21
EYN/A
EPS(NY)-5.26
Fwd EYN/A
FCF(TTM)-3.52
FCFYN/A
OCF(TTM)-3.46
OCFYN/A
SpS0.02
BVpS13.15
TBVpS13.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.34%
ROE -34.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.82%
ROA(5y)-45.5%
ROE(3y)-35.98%
ROE(5y)-518.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 191.42%
Cap/Sales 335.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.03
Quick Ratio 19.03
Altman-Z 4.34
F-Score6
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)251.94%
Cap/Depr(5y)197.59%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.02%
EPS Next Y-2.09%
EPS Next 2Y-0.54%
EPS Next 3Y2.66%
EPS Next 5Y2.81%
Revenue 1Y (TTM)6410%
Revenue growth 3YN/A
Revenue growth 5Y-56.77%
Sales Q2Q%N/A
Revenue Next Year15532.7%
Revenue Next 2Y296.32%
Revenue Next 3Y1012.85%
Revenue Next 5Y602.45%
EBIT growth 1Y-31.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.56%
EBIT Next 3Y-5.1%
EBIT Next 5YN/A
FCF growth 1Y-105.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.78%
OCF growth 3YN/A
OCF growth 5YN/A